All SARS-CoV-2 articles
-
News‘Low-sugar’ vaccine can provide broad immunity against coronavirus variants
A universal vaccine for coronaviruses removes sugar molecules from an area of a coronavirus spike protein that rarely mutates and creates effective and plentiful antibodies to inactivate the virus.
-
NewsUKHSA highlights pathogens of greatest risk to public health in bid to boost preparedness
The UK Health Security Agency (UKHSA) has today published its view on the pathogen families that could pose the greatest risk to public health, in a bid to focus and guide preparedness efforts against these threats.
-
NewsScientists ID natural products targeting SARS-CoV-2 - including caffeine
Researchers used computational methods to identify potential inhibitors of SARS-CoV-2 spike proteins, revealing promising natural compounds for guiding antiviral drug development, including caffeine.
-
NewsAntibody-based therapy is several steps closer to treat lethal mucormycosis
A new paper discusses the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the Mucorales fungus to invade human cells and cause mucormycosis, which has high mortality rates in people with weakened immune systems.
-
NewsMcMaster leads Canada’s first-ever guidelines for Post COVID-19 Condition
A team of experts from McMaster University has led the creation of Canada’s first-ever comprehensive guidelines for diagnosing, managing, preventing, and treating post COVID-19 condition (PCC), more commonly known as long COVID.
-
NewsCOVID-19 pandemic worsened mother and infant birth outcomes
Mothers who became pregnant after the start of the pandemic, those who experienced moderate-to-severe infections during pregnancy, and those who had infections during the third trimester were more likely to have adverse outcomes.
-
NewsCeSPIACE: A broad-spectrum peptide inhibitor against variable SARS-CoV-2 spikes
CeSPIACE, a small remodified peptide, is able to block the binding of ACE2 receptor and the spike protein on SARS-CoV-2 and its variants. Hence, the cheap and simple peptide could treat COVID-19 infection and prevent reinfection after exposure of the virus.
-
NewsSymptoms of long-COVID can last up to two years after infection with COVID-19
According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. In more than half of them the symptoms persisted for two years.
-
NewsCause of post-COVID inflammatory shock in children identified
MIS-C is a serious inflammatory shock that affects children and can occur several weeks after a COVID infection. Researchers have found that reactivation of a pre-existing, dormant infection with the Epstein-Barr virus triggers an excessive inflammatory response.
-
NewsMulti-dose vaccines administered in the same site boost immune response
New research suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an important strategy for providing immunity as quickly as possible during a pandemic or disease outbreak.
-
NewsInhaled COVID vaccine study begins recruitment for phase-2 human trials
Researchers have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. Findings from the phase-1 trial indicate that the vaccine is more effective at inducing immune responses than traditional injected vaccines are.
-
NewsBAADesign enables the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants
BAADesign offers a powerful tool for reengineering monoclonal antibodies to combat emerging SARS-CoV-2 variants, providing a scalable solution for future pandemic preparedness, according to a new study.
-
NewsScientist who deployed glowing stars to detect disease named fellow of the Royal Society of Chemistry
The man who turned the science of glow-in-the-dark stars into ways to detect disease, Professor Richard Willson, has been elected as a fellow of the Royal Society of Chemistry.
-
NewsNew COVID-flu vaccine platform could provide broad, lasting protection
Researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both COVID-19 and influenza, and broader immunity to different flu strains.
-
NewsLung abnormalities seen in children and teens with long COVID
An advanced type of MRI uncovers significant lung abnormalities in children and adolescents with long COVID, according to a new study. PREFUL MRI doesn’t require the use of radiation or intravenous contrast agents and can be done while the patient breathes freely.
-
NewsPaxlovid’s impact on hospitalization and death in COVID-vaccinated older adults far weaker than previously thought
A new study overturns the assumption that Paxlovid’s effectiveness in reducing COVID-19 hospitalizations and deaths in unvaccinated adults also applies to vaccinated adults.
-
NewsMachine learning framework can decipher immune system’s record of past infections
A novel machine learning framework can decipher an individual’s immune system’s record of past infections and diseases, providing a powerful tool with the potential for diagnosing autoimmune disorders, viral infections, and vaccine responses with precision.
-
NewsNew modeling approach could help design antivirals for shape-shifting viruses
New research utilizes an innovative computational modeling approach to capture the complex and diverse shapes that viral proteins can adopt.
-
NewsBat genome signposts new potential pathway to fight viruses with genomic characterization
A promising discovery has been made from a study that deciphers how bats are more resistant to viral infections than human using genome annotations of transposable elements in bats to pave a way for adapting the bats’ immunity against future viral outbreaks.
-
NewsNasal COVID-19 vaccine to enter US clinical trials
A nasal vaccine for COVID-19 is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA).